Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Neural Transm (Vienna) ; 121(5): 521-30, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24407377

RESUMEN

This study aimed at providing real-life baseline, injection and outcome data for the treatment of various forms of spasticity with onabotulinumtoxin A in Germany. Prospective data were collected in an open multicenter patient registry from 2005 until 2010, encompassing the experience of ten specialized German centers in the treatment of spasticity using onabotulinumtoxin A in 508 patients with a total of 2005 treatment sessions. Disease entities comprised spasticity following stroke (both ischemic and hemorrhagic), traumatic brain injury, multiple sclerosis, cerebral palsy, and anoxia. Sustained improvement was observed in a variety of outcome parameters including goal attainment and motor performance scores for up to five repeated injection sessions. No significant differences between disease entities or between upper and lower limb treatment were observed with regard to efficacy and safety following onabotulinumtoxin A treatment. Minor to moderate side effects were reported in <1 % of the study population. We conclude that repetitive treatment of focal and multifocal spasticity with onabotulinumtoxin A provides a safe and efficacious therapeutic strategy for patients with different disease entities of the central nervous system.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Espasticidad Muscular/tratamiento farmacológico , Fármacos Neuromusculares/uso terapéutico , Adulto , Toxinas Botulínicas Tipo A/efectos adversos , Femenino , Alemania , Humanos , Extremidad Inferior , Masculino , Persona de Mediana Edad , Espasticidad Muscular/etiología , Fármacos Neuromusculares/efectos adversos , Estudios Prospectivos , Sistema de Registros , Resultado del Tratamiento , Extremidad Superior
2.
BMC Neurol ; 10: 9, 2010 Jan 21.
Artículo en Inglés | MEDLINE | ID: mdl-20089201

RESUMEN

BACKGROUND: In idiopathic Parkinson's disease (IPD) transcranial sonography (TCS) represents an alternative diagnostic method to verify clinical diagnosis. Although the phenomenon of an increased echogenicity of the Substantia nigra (SN) is well known this method is still not widly used in the diagnostic workup. Until now reliability of this method is still a matter of debate, partly because data only existed from a few laboratories using the same ultrasound machine. Therefore our study was conducted to test the reliability of this method by using a different ultrasound device and examining a large population of control and IPD subjects by two examiners to calculate interobserver reliability. METHOD: In this study echogenicity of SN was examined in 199 IPD patients and 201 control subjects. All individuals underwent a neurological assessment including Perdue pegboard test and Webster gait test. Using a Sonos 5500 ultrasound device area of SN was measured, echogenicity of raphe, red nuclei, thalamus, caudate and lenticular nuclei, width of third and lateral ventricle were documented. RESULTS: We found a highly characteristic enlargement of the SN echogenic signal in IPD. The cut-off value for the SN area was established using a ROC curve with a sensitivity of 95% corresponding to an area of SN of 0.2 cm2 and was found to be equivalent to the cut-off values of other studies using different ultrasound devices. CONCLUSIONS: Our study shows that TCS is a reliable and highly sensitive tool for differentiation of IPD patients from individuals without CNS disorders.


Asunto(s)
Ecoencefalografía/métodos , Enfermedad de Parkinson/diagnóstico por imagen , Enfermedad de Parkinson/diagnóstico , Adulto , Factores de Edad , Anciano , Encéfalo/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/patología , Curva ROC , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Adulto Joven
3.
Knee Surg Sports Traumatol Arthrosc ; 18(2): 265-8, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19826783

RESUMEN

Generally, outcome after surgical repair of complete Achilles tendon rupture is good. However, some patients have ongoing problems with dorsiflexion of the ankle joint. We report on eight patients, who did not achieve heel contact because of reduced ankle dorsiflexion 5 months after surgical repair of complete Achilles tendon rupture. All patients received at least three cycles of injections with 200-300 units of Botulinum toxin A (BOTOX) into the gastrocnemius and soleus muscle. Weakening of the triceps surae by Botulinum toxin allowed patients to perform the required exercises and to tolerate casting at night. Thus, all patients were able to tolerate plantigrade foot position 9 months after beginning of Botulinum toxin treatment. At final follow-up after 2 years, pain had significantly improved, and a mean dorsiflexion of 21 degrees was reached. In conclusion, treatment of the calf muscles with BOTOX is a safe and effective method to improve restricted dorsiflexion in patients after Achilles tendon repair.


Asunto(s)
Tendón Calcáneo/cirugía , Toxinas Botulínicas Tipo A/administración & dosificación , Fármacos Neuromusculares/administración & dosificación , Complicaciones Posoperatorias/tratamiento farmacológico , Rango del Movimiento Articular , Tendón Calcáneo/lesiones , Adulto , Articulación del Tobillo , Moldes Quirúrgicos , Estudios de Cohortes , Terapia Combinada , Femenino , Humanos , Inyecciones Intramusculares , Masculino , Modalidades de Fisioterapia , Recuperación de la Función , Rotura Espontánea , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...